Dr. Michael J. Hurd, PH.D. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 17 Atlantic Ave, Suite 4, Ocean View, DE 19970 Phone: 302-539-5986 Fax: 410-997-2805 |
News Archive
Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated, in part, by the drug memantine (marketed in the United States as Namenda), which is currently FDA-approved to treat moderate-to-severe Alzheimer's disease and was, in part, developed by Stuart A. Lipton, M.D., Ph.D., Director of the Del E. Web Center for Neuroscience, Aging and Stem Cell Research at Sanford-Burnham Medical Research Institute (Sanford-Burnham).
A new study supports the use of a DNA-based "biomarker" blood test as a complement to the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. University of Cincinnati (UC) researchers report their findings online ahead of print in the British Journal of Cancer.
In tandem with the Food and Drug Administration's quest to dramatically reduce Salmonella-related food poisoning, National Pasteurized Eggs (NPE) www.SafeEggs.com, the country's largest shell egg pasteurizer, opened a new state-of-the-art plant that more than doubles its production and expands Americans' access to eggs free from dangerous egg-related Salmonella-enteritidis.
SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced that patient enrollment was completed in March in its dermaPACEā¢ Phase III pivotal, randomized, double-blinded, sham controlled, multicenter clinical trial comparing its Pulsed Acoustic Cellular Expression technology, utilizing the dermaPACEā¢ tissue regeneration device, to sham control for the treatment of diabetic foot ulcers.
› Verified 8 days ago